NASDAQ$PRME
Prime Medicine Inc · Q4 2025 earnings
Q4 2025 earnings · · Before market open · Investor relations
Briefing
Prime Medicine reported Q4 2025 financial results for its gene-editing programs.
Prime Medicine reported fourth-quarter and full-year 2025 financial results for its Prime Editing platform, including cash runway, collaboration revenue, and development milestones.
- Prime Editing gene therapy platform.
- FY2025 cash position and operating expenses.
- Partnerships with large pharma potential.
- Preclinical and early clinical pipeline.
- Manufacturing and delivery challenges for gene editing.
Headline financials
Revenue & EPS history
Prime Medicine · Revenue · Quarterly
$1.65M
Forward guidance
Runway and 2026 development milestones for lead liver and ex vivo programs.
Tailwinds
- Differentiated precise gene editing technology.
- Broad pipeline across genetic diseases.
- IP and platform partnerships.
Headwinds
- Early stage with substantial burn.
- Delivery and manufacturing scale-up risk.
- Competitive CRISPR landscape.
Historical earnings impact
How earnings announcements have historically affected this stock's price.
Avg. return before/after earnings
Based on 14 quarterly earnings reports · overlaid with Q4 2025
-1.7%
Avg return
Earnings day
-7.2%
Avg return
5 days after
-10.8%
Avg return
30 days after
29%
5 / 17 earnings
Positive
+26.6%
Q1 2025
Best reaction
-9.8%
Q3 2024
Worst reaction
| Quarter | Report date | Reaction (Day 0) | +5 days | +30 days |
|---|---|---|---|---|
| Q4 2025 | -8.2% | -13.9% | -28.8% | |
| Q3 2025 | -9.1% | -15.1% | -10.5% | |
| Q1 2025 | +26.6% | -7.5% | +15.9% | |
| Q4 2024 | +4.1% | -4.5% | -17.8% | |
| Q3 2024 | -9.8% | -23.8% | -31.4% | |
| Q2 2024 | -4.5% | -2.5% | -19.3% | |
| Q1 2024 | +12.2% | +18.2% | +14.9% | |
| Q4 2023 | +1.6% | -2.4% | -18.9% | |
| Q3 2023 | +17.0% | +13.1% | +21.6% | |
| Q2 2023 | -7.5% | -14.9% | -13.3% | |
| Q1 2022 | -9.4% | -10.5% | +3.2% | |
| Q1 2023 | -9.4% | -10.5% | +3.2% | |
| Q4 2020 | -9.7% | -11.7% | -21.9% | |
| Q4 2022 | -9.7% | -11.7% | -21.9% | |
| Q3 2022 | -4.4% | -8.1% | -19.4% | |
| Q3 2021 | -4.4% | -8.1% | -19.4% | |
| Q4 2021 | -4.4% | -8.1% | -19.4% | |
| Q2 2021 | — | — | — | |
| Q1 2021 | — | — | — | |
| Q4 2019 | — | — | — |
Discussion
Share your read of this quarter. Sign-in carries your eToro identity.
Join the conversation
Sign in with eToro to post your read of this quarter and vote on others'.
Sign in with eToro